Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI)
Status: | Recruiting |
---|---|
Conditions: | Infectious Disease |
Therapuetic Areas: | Immunology / Infectious Diseases |
Healthy: | No |
Age Range: | 18 - 100 |
Updated: | 10/1/2017 |
Start Date: | October 1, 2017 |
End Date: | December 31, 2019 |
Contact: | Herbert L DuPont, MD |
Email: | herbert.l.dupont@uth.tmc.edu |
Phone: | 713 500 9366 |
Phase II. Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI)
To establish optimal dosing of lyophilized FMT product in the treatment of recurrent C.
difficile infection
difficile infection
This is a single center, randomized, parallel assignment, double-blinded, safety and efficacy
study to be conducted in subjects with recurrent CDI. Approximately 300 subjects will be
enrolled in the study and randomized at 1:1:1 ratio to receive lyophilized donor intestinal
bacteria with various doses in capsules. All subjects will be followed for approximately 180
days following FMT for safety.
study to be conducted in subjects with recurrent CDI. Approximately 300 subjects will be
enrolled in the study and randomized at 1:1:1 ratio to receive lyophilized donor intestinal
bacteria with various doses in capsules. All subjects will be followed for approximately 180
days following FMT for safety.
Inclusion Criteria:
- Sexually active female subjects of child-bearing potential must agree to use an
effective method of birth control during the treatment and follow-up period
- Female subjects of child-bearing potential must have a negative pregnancy test on the
day of the procedure.
- Subject willing to sign an informed consent form
- Subject deemed likely to survive for ≥ 1 year after enrollment
- Able to follow study procedure and follow-ups
- Subjects' attending physician will provide non-transplant care for the subject
- Diagnosed by medical history of ≥ 3 bouts of CDI in outpatients or ≥ 2 bouts of RCDI
in an inpatient with ≥ 2 positive fecal tests for C. difficile toxin
- Received at least one course of adequate antibiotic therapy for CDI (≥ 10 days of
vancomycin or metronidazole or fidaxomicin) since last bout of CDI
- Have a 4C refrigerator at home to keep the second dose FMT for overnight
Exclusion Criteria:
- Unable to take capsules orally
- Requiring systemic non-C. difficile antibiotic therapy within 14 days prior to FMT
- Actively taking Saccharomyces boulardii or other probiotic at the time of FMT other
than that found in fortified foods
- Need for continuing use of drugs with CDI activity: oral vancomycin, oral or IV
metronidazole, fidaxomicin, rifaximin or nitazoxanide at the time of FMT and after FMT
- Severe underlying disease such that the patient is not expected to survive for one or
more years or unstable medical condition requiring daily change in treatments
We found this trial at
1
site
Houston, Texas 77030
Principal Investigator: Herbert L DuPont, MD
Phone: 713-500-9371
Click here to add this to my saved trials